Skip to main content
    D

    Design Therapeutics Inc (DSGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.84
    -0.08 (-0.81%)

    Market Cap: $670.46M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Design Therapeutics Inc (DSGN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Design Therapeutics (DSGN) has a market cap of $670.46M and an enterprise value of $655.21M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 10.68% from a year earlier.

    Total Valuation

    Enterprise value is 2.27% below the market cap, as cash exceeds debt.

    Market Cap$670.46M
    Enterprise Value$655.21M
    Latest price (Nov 17, 2026)$9.84

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.85% in the quarter ended Sep 30, 2026 and grew 5.51% a year over 2 years.

    Shares Outstanding63.04M
    Shares Change (YoY)+10.68%
    Shares Change (QoQ)+0.85%
    Share Count Growth (2Y CAGR)+5.51%

    Price Statistics

    The stock is up 33.51% over 52 weeks and trades 14.29% below its 50-day average.

    Beta (1Y)1.33
    52-Week Change+33.51%
    1-Month Change-7.52%
    3-Month Change-38.27%
    6-Month Change-6.20%
    5-Year Change-31.89%
    Total Return (1Y)+33.51%
    Total Return (3Y CAGR)+64.25%
    Total Return (5Y CAGR)-14.09%
    Return vs SPY (1Y)+18.09%
    Max Drawdown (1Y)-39.34%
    Max Drawdown (3Y)-62.80%
    Sharpe Ratio (1Y)0.37
    Correlation with SPY (1Y)0.26
    50-Day Average$11.48
    200-Day Average$12.18
    52-Week Range$7.25 to $17.25
    RSI (14 Days)39.6
    Average Volume (20 Days)345.65K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 16.78x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio16.78x
    Quick Ratio16.78x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -36.64% over the last 12 months, against a 5-year average of -21.21%.

    Return on Equity (ROE)-36.64%
    Return on Assets (ROA)-34.17%
    ROE (5Y Average)-21.21%
    ROA (5Y Average)-20.25%
    ROIC (5Y Average)-29.54%

    Scores

    DSGN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit$14.74M
    Operating Income-$82.28M
    Pretax Income-$74.09M
    Net Income-$74.09M
    Reported EPS (TTM)-$1.20

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 93.26% of the $216.81M in total assets.

    Cash and Equivalents$15.25M
    Total Debt$0
    Net Cash$15.25M
    Net Cash Per Share$0.24
    Working Capital$201.21M
    Shareholder Equity$202.20M
    Book Value Per Share$3.21
    Total Assets$216.81M
    Total Liabilities$14.61M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $70.00K of capital spending, operating cash flow left -$59.37M of free cash flow.

    Operating Cash Flow-$59.30M
    Capital Expenditures$70.00K
    Free Cash Flow-$59.37M
    FCF Per Share-$0.95
    Depreciation and Amortization$1.29M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-13.42%
    Tangible Book Per Share Growth (2Y CAGR)-13.42%

    Revenue and profit by year

    Dividends and Yields

    DSGN does not pay a dividend. Its free cash flow yield is -9.57%.

    FCF Yield-9.57%
    Buyback Yield-10.12%
    Shareholder Yield-10.12%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About DSGN

    What is DSGN's market cap?

    Design Therapeutics has a market cap of $670.46M. Its enterprise value, which adds debt and subtracts cash, is $655.21M.

    How many shares of DSGN are outstanding?

    Design Therapeutics has 63.04M shares outstanding. The count is up 10.68% from a year earlier.

    Does DSGN pay a dividend?

    No. Design Therapeutics does not pay a dividend.

    How much debt does DSGN have?

    Design Therapeutics has $0 of total debt and $15.25M of cash and equivalents, a net cash position of $15.25M.